C4 Therapeutics raises $117M net in underwritten offering of stock and warrants

C4 Therapeutics, Inc.

Offering includes 21.9M shares, pre-funded warrants for 28.7M shares, and Class A/B warrants for 50.6M shares each.
Combined price per unit $2.47; net proceeds ~$117M, extending cash runway to end of 2028.
If all warrants cash exercised, total net proceeds could reach $341.7M.
Class A warrants expire on earlier of 30 days post Phase 1b data or 5 years; Class B warrants mandatory if stock >$6.66.
Pre-funded warrants have $0.0001 exercise price and no expiration; all warrants subject to beneficial ownership limits.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.